

FOI 2923

3rd March 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question A.

Please provide the number of migraine patients treated in the last 4 months with:

- **Atogepant (Aquipta)**
- **Erenumab (Aimovig)**
- **Eptinezumab (Vyepiti)**
- **Fremanezumab (Ajoovy)**
- **Galcanezumab (Emgality)**
- **Rimegepant (Vydura)**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin)**

Response:

- Atogepant (Aquipta): 0
- Erenumab (Aimovig): 0
- Eptinezumab (Vyepiti): 3
- Fremanezumab (Ajoovy): 0
- Galcanezumab (Emgality): 0
- Rimegepant (Vydura): 0
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin): approx. 80 patients per month at clinic

Question B.

How many patients have you treated in the last 4 months for acute migraine with:

- **Rimegepant (Vydura)**

Response:

- Rimegepant (Vydura) 0

Question C.

Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Response:

Yes

Email: Foi.Team@Southerntrust.hscni.net